N/A N=16 Iron Bioavailability From MyPyramid Menus
Nonheme Iron Absorption
Primary: Nonheme Iron Absorption — 2.31 percentage of nonheme Iron absorbed
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Iron Bioavailability of Fortified Oat Drink
Iron Absorption
Primary: Percent Iron Absorption — 7.14; 5.65 percentage of Iron absorbed
N/A N=25 Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Tailored Control in Milk
Growth and Development
Primary: Fractional Iron Absorption — 2.08; 1.25 % Iron Absorbed — p=0.0944
N/A N=77 Measurements of Body Iron Excretion of Healthy Adults
Healthy
Primary: Rate of Iron Excretion. — 1.07; 1.69; 1.08 milligrams per day — p=< 0.05
Phase 4 N=88 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23
N/A N=56 Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions
Anemia
Primary: The Hemoglobin of the Subjects at Baseline and 6 Weeks — 0.38; 0.29; 0.57 g/dl
N/A N=142 Massive Iron Deposit Assessment
Iron Overload · Excessive Body Iron Burden
Primary: Hepatic Iron Content in the Liver Using Liver Biopsy — 19.8 mcg
Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
N/A N=197 Iron Depletion and Replacement in Blood Donors
Anemia
Primary: Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation — 116; 17 Participants
Phase 4 N=198 Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
Primary: Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders). — 60; 34 Participants
N/A N=17 Effects of Calcium and Phytate on Zinc Absorption
Dietary Zinc Absorption
Primary: Zinc Absorption — 32.8; 26.9; 39.4; 26.2 Percentage of Zinc-65 absorbed — p=0.17
Phase 1 N=8 Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 17.56; 32.95 μg/mL
Phase 2 N=75 Probing the Synergistic Effect of Pre-Biotics & Iron Fortificants in Anemic Subjects
Iron-deficiency
Primary: Change in Hemoglobin Concentration From Baseline to 90 Days — 11.44; 11.58; 11.54; 11.61 g/dL
Phase 4 N=1,000 Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes
Anemia · Diarrhea · Iron
Primary: Incidence of Diarrhea — 201; 204; 260; 224 episodes
N/A N=22 Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis
Cystic Fibrosis · Anemia, Iron-Deficiency
Primary: Change From Baseline in Hemoglobin Concentration (gm/dl) — 0.12; 0.09 gm/dl — p=0.81
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
N/A N=251 Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years
Iron Deficiency
Primary: The Primary Outcome is Iron Depletion, and Will be Defined as Serum Ferritin <10 mcg/L. — 64; 71; 13; 10 participants — p=0.42
Phase 4 N=13 Alternate Day Versus Daily Oral Iron Therapy in Adolescents
Iron Deficiency Anemia · Heavy Menstrual Bleeding · Abnormal Uterine Bleeding
Primary: Percentage of Eligible Patients Enrolled. — 13 Participants
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
N/A N=16 Oral Iron for Erythropoietic Protoporphyrias
Erythropoietic Protoporphyria · EPP · X-linked Protoporphyria
Primary: Change in Erythrocyte Protoporphyrin Levels — 2314.6; 2240.4 µg/dL
Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05
Phase 4 N=243 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants
Phase 1 N=37 Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
Iron Deficiency, Anaemia in Children · Iron-Deficiency
Primary: Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1 — 2.4518; 1.1632; 0.5299 mg/L
Phase 2 N=12 Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
Kidney Failure
Primary: Net Iron Delivery From SFP Via the Dialysate — 692 microgram
Phase 2 N=15 Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Anaemia
Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
Phase 2 N=200 Efficacy of Enteral Iron Supplementation in Critical Illness
Anemic, Critically Ill Patients
Primary: Hematocrit — 29.3; 29.1; 28.6; 28.2 percentage of RBC in blood
Phase 4 N=1,025 Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron
Iron Deficiency Anemia (IDA)
Primary: Multidimensional Assessment of Fatigue (MAF) Scores — -8.8; -8.1 units on a scale
Phase 2 N=12 Intravenous Iron Metabolism in Restless Legs Syndrome
Restless Legs
Primary: Duration Off Treatment — 6; 3; 2; 0 participants
Phase 4 N=15 Iron Indices and Intravenous Ferumoxytol: Time to Steady State
Iron Deficiency Anemia
Primary: Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize — 2 weeks